This document provides an overview of potential adverse effects associated with medications used for fracture prevention, discussing whether these adverse effects are clinically relevant. It summarizes evidence related to adverse effects of calcium, vitamin D, bisphosphonates, denosumab, teriparatide, and strontium ranelate from various clinical trials and studies. It concludes with treatment recommendations regarding calcium and vitamin D intake and notes that while bisphosphonates and other antiresorptive medications can have adverse effects like osteonecrosis of the jaw or atypical fractures, their benefits in fracture prevention are still considered to outweigh these risks for most patients.